Myriad Genetics, Inc. announced that Dennis Langer, a member of the Board of Directors of Myriad Genetics, Inc, notified the Company that he is resigning as a director, effective June 30, 2022. In connection with his resignation, the Company and Dr. Langer entered into a one-year consulting agreement, which will be effective upon his resignation as a director, under which Dr. Langer will provide consulting services to the Company upon its request at an hourly rate and for the continued vesting of his equity awards pursuant to their terms during the term of the consulting agreement. Dr. Langer's resignation was not a result of any disagreement with the Company or due to any matter relating to the Company's operations, policies, or practices.